Estimating Quality of Life in Greek Patients with Hidradenitis SuppurativaVassiliki Tzanetakou1*, Theodora Kanni1, Kyriakoula Merakou2, Anastasia Barbouni2 and Evangelos Giamarellos-Bourboulis J1
- Corresponding Author:
- Vassiliki Tzanetakou
4thDepartment of Internal Medicine
University of Athens, Medical School, Greece
Tel: +30 210 58 31 985
Fax: +30 210 53 26 446
E-mail: [email protected]
Received date: April 28, 2014; Accepted date:March 08, 2015; Published date: March 15, 2015
Citation: Tzanetakou V, Kanni T, Merakou K, Barbouni A, Evangelos Giamarellos- Bourboulis J (2015) Estimating Quality of Life in Greek Patients with Hidradenitis Suppurativa. Primary Health Care 5:181. doi:10.4172/2167-1079.1000181
Copyright: © 2015 Tzanetakou V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Hidradenitis suppurativa (HS) is a chronic, relapsing skin disorder causing physical impairment and severe negative effects on patients’ quality of life (QoL). The current study aims to estimate the impairment of QoL in HS and the role of disease advancement as a worsening factor. Patients and Methods: Fifty patients and fifty healthy controls were sex and age matched and completed two questionnaires, the ‘Dermatology Life Quality Index’ (DLQI) and the ‘SF-36v2TM Health Survey’ (SF36). Comparisons were carried out between patients of different Hurley stage and between patients and controls’ subgroups. The results of both questionnaires were correlated. Results: According to Hurley system,15 patients manifested first-stage HS,13 second-stage HS, while 22 patients exhibited third-stage disease severity. HS patients experienced greater impact on their QoL compared to healthy controls (total mean DLQI score 13.10 ± 1.19 vs.1.44 ± 0.32, p<0.001 and total mean SF36 score 53.13 ± 3.34 vs.79.43 ± 1.38, p<0.001). Elevated score was attributed mainly to bodily pain and embarrassment due to skin disease. Patients with advanced stage of disease (Hurley III) obtained significantly higher score compared to patients with milder stage (Hurley I and II) in both questionnaires (mean DLQI score 18.55 ± 1.51 vs. 8.82 ± 1.3, p<0.001 and mean SF36 score 40.43 ± 4.44 vs.70.26 ± 3.1,p<0.001, respectively). Total DLQI and SF36 scores were excellently correlated (p<0.01, Spearman’s correlation coefficient -0.771). Conclusion: Patients with HS suffer a devastating impact on QoL. The phenomenon is greater within advanced disease stages.